Bluejay Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 19, 2024 12:04 ET
|
Bluejay Therapeutics
REDWOOD CITY, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company rapidly progressing transformative therapies for viral hepatitis and...
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors
November 21, 2024 09:00 ET
|
Bluejay Therapeutics
SAN MATEO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a clinical-stage biopharmaceutical company rapidly progressing transformative therapies for viral hepatitis and other...
Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD)
November 15, 2024 11:00 ET
|
Bluejay Therapeutics
Phase 2 study results to be presented at The Liver Meeting® 2024 of AASLD BJT-778 900 mg dosed every four weeks showed promising efficacy by Week 24: 100% virologic response with 50% of participants...
Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress
June 05, 2024 08:00 ET
|
Bluejay Therapeutics
100% of treated patients in Arm 1 achieved virologic response by Week 28 Most patients also achieved ALT normalization and composite response BJT-778 was well tolerated across all arms at doses...
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D
May 29, 2024 08:00 ET
|
Bluejay Therapeutics
SAN MATEO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private clinical-stage biopharmaceutical company focused on viral and liver diseases with unmet medical needs, today...
Bluejay Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver (EASL) Congress 2024
May 22, 2024 08:00 ET
|
Bluejay Therapeutics
SAN MATEO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics today announced it will present new data from its ongoing Phase 2 trial evaluating the potential of BJT-778, an...
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
May 09, 2024 07:00 ET
|
Bluejay Therapeutics
SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a leader in the development of novel therapeutics, today announced the successful closure of a $182 million Series C...
Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection
March 25, 2024 08:00 ET
|
Bluejay Therapeutics
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a private clinical-stage biopharmaceutical company focused on viral and liver diseases, today announced the European...
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development
September 21, 2023 07:55 ET
|
Bluejay Therapeutics
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the...
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment
June 01, 2023 18:14 ET
|
Bluejay Therapeutics
SAN MATEO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a company dedicated to developing innovative treatments for viral and liver diseases, announces the successful completion...